In a May 7, 2024 press release, Seragon Biosciences announced that its aging intervention drug candidate, SRN-901, achieved one of the largest extensions of
How the body’s fuel sensors—mTOR, IGF-1, AMPK, and sirtuins—shape aging, and what human studies say about nutrient sensing, diet, exercise, drugs, and biomarkers that
Caloric restriction mimetics offer the benefits of calorie reduction without extreme diets, targeting pathways linked to aging for a longer, healthier life.
Rapamycin shows potential in extending lifespan, improving healthspan, and enhancing oral health, making it a key player in anti-aging research and human longevity.